The one thing that is verified: Micron is spending, and earning, at a new scale
Most of the AI-infrastructure story in mid-2026 is opinion: price targets, ratings and bullish notes. One part of it is hard data. Micron Technology, a memory-chip maker, spent $15.857 billion on capital expenditure (factories and equipment) in fiscal 2025, according to its SEC filings.1 That is nearly double the $8.386 billion it spent in fiscal 20241 and more than double the $7.676 billion in fiscal 2023.1
The pace has kept rising. In the first quarter of fiscal 2026, Micron spent $5.389 billion in three months.1 That compares with $3.206 billion in the same quarter a year earlier1 and $1.796 billion two years earlier, so the latest quarter is about three times the 2024 level.1 This is a company putting money into capacity at a speed its own recent history does not match.
The cash balance has grown too. Micron reported $9.731 billion in cash at the end of fiscal Q1 2026,2 $13.908 billion at Q22 and $24.995 billion at Q3.2 A year earlier, at Q3 2025, it held $10.163 billion, so the balance is about two and a half times as large.2
Costs have risen far more slowly than spending. Micron's cost of revenue (what it costs to make what it sells) was $16.956 billion in fiscal 2023,3 $19.498 billion in fiscal 20243 and $22.505 billion in fiscal 2025.3 In the first fiscal quarter of 2026 it was $5.997 billion, against $5.361 billion a year before.3
One limit on this data: our verified set holds Micron's spending, cash and costs, but not its revenue or profit. Rising cash is a good sign, but it is not the same as profit. We cannot say from these figures how much of the cash came from earnings and how much from other sources.
Where Micron sits in the AI supply chain
Our knowledge graph links Micron to the companies building AI capacity. It records Micron as a supplier to Amazon Web Services and to Meta Platforms, and as located in Taiwan.4 Sandisk, the other memory name in this week's analyst notes, was spun off from Western Digital, which owns it.4
On September 4, 2026, analyst K.C. Rajkumar of Lynx Equity Strategies published a bullish analysis rating both Micron and Sandisk clear buys.5 The same day, ASML Holding, a chip-equipment maker, rose over 4% in what our records describe as a sympathy rally after a bullish analysis of a top chip name.6 A single note moved a neighbouring stock. That says as much about market mood as about any company's results.
Power and data centers: a strong story, on thinner sourcing
The same theme runs through the power companies that supply AI data centers. Our sector narrative records that Digital Realty raised its core FFO guidance (a profit measure used for property companies) and that Evercore ISI set a Street-high $350 price target on Bloom Energy.7
A July 3, 2026 article, "Bull of the Day: Bloom Energy (BE)", reports that Bloom was added to the Russell 1000 large-cap index and expanded its AI infrastructure partnerships.8 The writer, Nicholas Amicucci, argues that Bloom's ability to supply reliable, on-demand power to a demand profile that swings sharply sets it apart from competitors.8 That is his view, not a verified fact. Our checks found that only 46% of 520 claims from that publication's feed held up.8
Nuclear is a similar case. NuScale Power shares have fallen nearly 40% in 2026, yet Bank of America analyst Rinny Singh reiterated a buy rating in early August with a $12 target, implying roughly 24% upside.9 The source is a Motley Fool article, and only 22% of the 18 claims we checked from it held up. That is a small sample, but a weak one.9
The speculative end: quantum computing looks stretched
D-Wave Quantum shows the other side of the boom. Analyst Melissa Tucker described its stock as trading at a stretched 171 times sales, with projected 2026 revenue near $35 million and a fair-value estimate of $9.50 a share. She cited a delayed technology roadmap and D-Wave's reliance on a supplier that IonQ, a direct competitor, is set to acquire.10 Her estimate implies roughly 40% downside from the price at the time of her note.10
The share price is volatile. D-Wave fell about 10% on a Tuesday to $17.64, a drop of $1.88, after a 20% surge the previous day on an expanded partnership with AT&T and a bullish analyst initiation. The stock was still down 25% over the month.11 The $9.50 estimate and the $17.64 close come from different documents and dates, so we do not compute a gap between them. Our narrative also records SpaceX shares down more than 40% from their highs.7
Consumer names: a slow recovery
Away from AI, the picture is weaker. Our narrative groups Wendy's, GAP, Levi and Nike as showing weak traffic and slow recovery.7 At Nike, Bank of America analyst Lorraine Hutchinson lowered her price target because the sales recovery is taking longer than expected.12 On September 16, 2026, Seaport Global's Eric Gonzalez began coverage of Wendy's with a neutral rating.13 The stock fell nearly 6% that day, extending a decline that began when a take-private plan collapsed.14
Biotech: a different story that only loosely belongs here
Large-cap biotech is being discussed on its own terms. JPMorgan analyst Jessica Fye said several trends are developing at once in the sector: improving profitability, broader commercial diversification, a steady flow of clinical catalysts and continued business development opportunities.15 She also said investors should buy Alnylam Pharmaceuticals on the dip.15 On September 24, 2026, Goldman Sachs analyst Andrea Newkirk resumed coverage of Iovance Biotherapeutics with a buy rating and a $15 price target, and the shares rose.16 We see little direct link to the AI theme, so we treat biotech as a separate thread.
What this means for ordinary investors
Our dossier does not say how much of any particular index fund is made up of these companies, so we will not guess. Several of them are large enough that broad funds may hold some. Check your own fund's top holdings.
Via News's analysis of the data is this. The firmest evidence of an AI buildout is a company paying for it in filed accounts: Micron's spending and cash. The most excited commentary, on power and quantum names, relies on sources that held up only about half the time, or less, in our checks. Those stories may still be right. Treat them as claims to test, not facts.
What to watch
- Micron's next filing: whether capital spending keeps rising past the $5.389 billion quarterly level, and whether revenue and profit data show the cash pile is earned.1
- D-Wave's results: the company had scheduled its Q2 2026 report for August 6, 2026, before market open. Whether revenue approaches the roughly $35 million projection matters against a 171x sales multiple.17
- Summit Therapeutics: the FDA's target decision date for its ivonescimab application is November 14, 2026.18
